Ulotaront hydrochloride by Sumitomo Pharma America for Generalized Anxiety Disorder (GAD): Likelihood of Approval

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Generalized Anxiety Disorder (GAD).

Multiple drug targets for the treatment of influenza identified using AI program

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world

July 1, 2023

Survey: Americans want weight loss drugs despite high cost

Many Americans really want to lose weight — and a new poll shows nearly half of adults would be interested in taking a prescription drug

August 5, 2023

Whole-brain imaging data provides insights into roundworm neural activity

Joint research led by Yu Toyoshima and Yuichi Iino of the University of Tokyo has demonstrated individual differences in and successfully extracted commonalities from the

March 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.